Biotechnology
Compare Stocks
2 / 10Stock Comparison
VIVS vs SDGR
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Information Services
VIVS vs SDGR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Biotechnology | Medical - Healthcare Information Services |
| Market Cap | $4M | $992M |
| Revenue (TTM) | $142K | $255M |
| Net Income (TTM) | $-1M | $-103M |
| Gross Margin | 100.0% | 55.3% |
| Operating Margin | -80.7% | -64.7% |
| Total Debt | $942K | $109M |
| Cash & Equiv. | $11M | $231M |
VIVS vs SDGR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 25 | May 26 | Return |
|---|---|---|---|
| VivoSim Labs, Inc. (VIVS) | 100 | 72.3 | -27.7% |
| Schrödinger, Inc. (SDGR) | 100 | 51.8 | -48.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VIVS vs SDGR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
VIVS carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.53
- Rev growth 32.1%, EPS growth 91.2%, 3Y rev CAGR -54.2%
- -18.0% 10Y total return vs SDGR's -53.6%
SDGR is the clearest fit if your priority is quality and efficiency.
- -40.6% margin vs VIVS's -8.6%
- -15.3% ROA vs VIVS's -17.6%, ROIC -39.4% vs -8.5%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 32.1% revenue growth vs SDGR's 23.3% | |
| Quality / Margins | -40.6% margin vs VIVS's -8.6% | |
| Stability / Safety | Beta 0.53 vs SDGR's 1.72, lower leverage | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | -27.7% vs SDGR's -44.0% | |
| Efficiency (ROA) | -15.3% ROA vs VIVS's -17.6%, ROIC -39.4% vs -8.5% |
VIVS vs SDGR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
VIVS vs SDGR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
Evenly matched — VIVS and SDGR each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SDGR is the larger business by revenue, generating $255M annually — 1795.1x VIVS's $142,000. Profitability is closely matched — net margins range from -40.6% (SDGR) to -8.6% (VIVS). On growth, VIVS holds the edge at +8.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $142,000 | $255M |
| EBITDAEarnings before interest/tax | -$11M | -$159M |
| Net IncomeAfter-tax profit | -$1M | -$103M |
| Free Cash FlowCash after capex | -$11M | -$148M |
| Gross MarginGross profit ÷ Revenue | +100.0% | +55.3% |
| Operating MarginEBIT ÷ Revenue | -80.7% | -64.7% |
| Net MarginNet income ÷ Revenue | -8.6% | -40.6% |
| FCF MarginFCF ÷ Revenue | -74.8% | -58.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +8.3% | -1.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +19.7% | +1.2% |
Valuation Metrics
SDGR leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $4M | $992M |
| Enterprise ValueMkt cap + debt − cash | -$7M | $871M |
| Trailing P/EPrice ÷ TTM EPS | -0.83x | -9.42x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 25.54x | 3.88x |
| Price / BookPrice ÷ Book value/share | 0.20x | 2.68x |
| Price / FCFMarket cap ÷ FCF | — | 79.66x |
Profitability & Efficiency
SDGR leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
VIVS delivers a -27.6% return on equity — every $100 of shareholder capital generates $-28 in annual profit, vs $-31 for SDGR. VIVS carries lower financial leverage with a 0.09x debt-to-equity ratio, signaling a more conservative balance sheet compared to SDGR's 0.30x. On the Piotroski fundamental quality scale (0–9), SDGR scores 4/9 vs VIVS's 3/9, reflecting mixed financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -27.6% | -30.8% |
| ROA (TTM)Return on assets | -17.6% | -15.3% |
| ROICReturn on invested capital | -8.5% | -39.4% |
| ROCEReturn on capital employed | -163.8% | -28.6% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.09x | 0.30x |
| Net DebtTotal debt minus cash | -$10M | -$121M |
| Cash & Equiv.Liquid assets | $11M | $231M |
| Total DebtShort + long-term debt | $942,000 | $109M |
| Interest CoverageEBIT ÷ Interest expense | -93.23x | — |
Total Returns (Dividends Reinvested)
VIVS leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in VIVS five years ago would be worth $8,198 today (with dividends reinvested), compared to $1,942 for SDGR. Over the past 12 months, VIVS leads with a -27.7% total return vs SDGR's -44.0%. The 3-year compound annual growth rate (CAGR) favors VIVS at -6.4% vs SDGR's -21.8% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -25.0% | -26.1% |
| 1-Year ReturnPast 12 months | -27.7% | -44.0% |
| 3-Year ReturnCumulative with dividends | -18.0% | -52.1% |
| 5-Year ReturnCumulative with dividends | -18.0% | -80.6% |
| 10-Year ReturnCumulative with dividends | -18.0% | -53.6% |
| CAGR (3Y)Annualised 3-year return | -6.4% | -21.8% |
Risk & Volatility
Evenly matched — VIVS and SDGR each lead in 1 of 2 comparable metrics.
Risk & Volatility
VIVS is the less volatile stock with a 0.53 beta — it tends to amplify market swings less than SDGR's 1.72 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SDGR currently trades 48.1% from its 52-week high vs VIVS's 26.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.53x | 1.72x |
| 52-Week HighHighest price in past year | $5.30 | $27.63 |
| 52-Week LowLowest price in past year | $1.25 | $10.95 |
| % of 52W HighCurrent price vs 52-week peak | +26.6% | +48.1% |
| RSI (14)Momentum oscillator 0–100 | 39.0 | 59.8 |
| Avg Volume (50D)Average daily shares traded | 80K | 1.3M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $18.00 |
| # AnalystsCovering analysts | — | 12 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
SDGR leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). VIVS leads in 1 (Total Returns). 2 tied.
VIVS vs SDGR: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is VIVS or SDGR a better buy right now?
For growth investors, VivoSim Labs, Inc.
(VIVS) is the stronger pick with 32. 1% revenue growth year-over-year, versus 23. 3% for Schrödinger, Inc. (SDGR). Analysts rate Schrödinger, Inc. (SDGR) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — VIVS or SDGR?
Over the past 5 years, VivoSim Labs, Inc.
(VIVS) delivered a total return of -18. 0%, compared to -80. 6% for Schrödinger, Inc. (SDGR). Over 10 years, the gap is even starker: VIVS returned -18. 0% versus SDGR's -53. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — VIVS or SDGR?
By beta (market sensitivity over 5 years), VivoSim Labs, Inc.
(VIVS) is the lower-risk stock at 0. 53β versus Schrödinger, Inc. 's 1. 72β — meaning SDGR is approximately 228% more volatile than VIVS relative to the S&P 500. On balance sheet safety, VivoSim Labs, Inc. (VIVS) carries a lower debt/equity ratio of 9% versus 30% for Schrödinger, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — VIVS or SDGR?
By revenue growth (latest reported year), VivoSim Labs, Inc.
(VIVS) is pulling ahead at 32. 1% versus 23. 3% for Schrödinger, Inc. (SDGR). On earnings-per-share growth, the picture is similar: VivoSim Labs, Inc. grew EPS 91. 2% year-over-year, compared to 45. 1% for Schrödinger, Inc.. Over a 3-year CAGR, SDGR leads at 12. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — VIVS or SDGR?
Schrödinger, Inc.
(SDGR) is the more profitable company, earning -40. 4% net margin versus -1727. 8% for VivoSim Labs, Inc. — meaning it keeps -40. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SDGR leads at -65. 2% versus -87. 6% for VIVS. At the gross margin level — before operating expenses — VIVS leads at 96. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — VIVS or SDGR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is VIVS or SDGR better for a retirement portfolio?
For long-horizon retirement investors, VivoSim Labs, Inc.
(VIVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 53)). Schrödinger, Inc. (SDGR) carries a higher beta of 1. 72 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VIVS: -18. 0%, SDGR: -53. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between VIVS and SDGR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.